Literature DB >> 7651738

The tumor suppressor gene WT1 inhibits ras-mediated transformation.

X N Luo1, J C Reddy, P L Yeyati, A H Idris, S Hosono, D A Haber, J D Licht, G F Atweh.   

Abstract

Wilms' tumor belongs to a small group of pediatric neoplasms that have served as paradigms of human cancers in which recessive mutations play a primary role in tumorigenesis. WT1 is a candidate tumor suppressor gene that is mutationally inactivated in a proportion of both familial and sporadic Wilms' tumors. Recent studies demonstrated that WT1 can partially suppress growth of a Wilms' tumor cell line in vitro and in vivo. We investigated the ability of WT1 to inhibit the expression of the transformed phenotype in non-Wilms' tumor cells. The expression of WT1 cDNA in ras-transformed NIH3T3 cells yielded large, flat cells that exhibited complete contact-inhibition. These morphologic changes were associated with decreased proliferation, suppression of clonogenicity in soft agar and inhibition of tumor growth in nude mice. Moreover, expression of WT1 in non-transformed NIH3T3 cells resulted in similar morphologic changes and profound resistance to transformation by an activated ras oncogene. These studies suggest that tumor inhibition by WT1 in these cells may be achieved by interference with the ras-mediated signalling pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7651738

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.

Authors:  Marianne K-H Kim; Thomas J McGarry; Pilib O Broin; Jared M Flatow; Aaron A-J Golden; Jonathan D Licht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

2.  A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1.

Authors:  R W Johnstone; R H See; S F Sells; J Wang; S Muthukkumar; C Englert; D A Haber; J D Licht; S P Sugrue; T Roberts; V M Rangnekar; Y Shi
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

3.  The role of NF-kappaB in the regulation of the expression of wilms tumor suppressor gene WT1.

Authors:  Y Chen; B R Williams
Journal:  Gene Expr       Date:  2000

4.  Expression and function of the leucine zipper protein Par-4 in apoptosis.

Authors:  S F Sells; S S Han; S Muthukkumar; N Maddiwar; R Johnstone; E Boghaert; D Gillis; G Liu; P Nair; S Monnig; P Collini; M P Mattson; V P Sukhatme; S G Zimmer; D P Wood; J W McRoberts; Y Shi; V M Rangnekar
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

Review 5.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Authors:  Vicki Huff
Journal:  Nat Rev Cancer       Date:  2011-01-20       Impact factor: 60.716

6.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

7.  WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression.

Authors:  Debra J Morrison; Marianne K H Kim; Windy Berkofsky-Fessler; Jonathan D Licht
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

8.  Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth.

Authors:  Y Oji; H Ogawa; H Tamaki; Y Oka; A Tsuboi; E H Kim; T Soma; T Tatekawa; M Kawakami; M Asada; T Kishimoto; H Sugiyama
Journal:  Jpn J Cancer Res       Date:  1999-02

Review 9.  RNA-Binding Proteins in Acute Leukemias.

Authors:  Konstantin Schuschel; Matthias Helwig; Stefan Hüttelmaier; Dirk Heckl; Jan-Henning Klusmann; Jessica I Hoell
Journal:  Int J Mol Sci       Date:  2020-05-12       Impact factor: 5.923

10.  In silico regulatory analysis for exploring human disease progression.

Authors:  Dustin T Holloway; Mark Kon; Charles DeLisi
Journal:  Biol Direct       Date:  2008-06-18       Impact factor: 4.540

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.